RSSCategory: Genetics

Trevor Heritage Joins Inspirata as Senior Vice President of Cancer Informatics

| February 21, 2017 | 0 Comments

Dr. Heritage is widely recognized for his work in the development of informatics systems for drug and performance chemical discovery, translational and personalized medicine, and pharmaceutical product development. San Francisco, CA, February 21, 2017  – Cancer diagnostics workflow solution provider Inspirata, Inc., is pleased to announce that Dr. Trevor Heritage has joined its executive team to […]

Continue Reading

‘Crosswalk’ Re-Launched to Make it Easier to Bridge the Gap Between Pathology, Precision Diagnosis and Precision Medicine

| February 20, 2017 | 0 Comments

Inspirata has just released new mobile and Web-based versions of “Crosswalk Insight: Oncology™,” a knowledge visualization platform that enables users to easily navigate through tumor images and the associated molecular pathways, targeted therapies and clinical trials. San Francisco, CA, February 20, 2017 – Cancer diagnostics and pathology workflow solution provider Inspirata®, Inc. announced today the re-launch […]

Continue Reading

Epigenetics Changes Promote Pancreatic Cancer Metastasis

| January 20, 2017 | 0 Comments

Courtesy of Clinical OMICs – Molecular Diagnostics in Personalized Medicine Johns Hopkins researchers have published new data that suggests epigenetic changes controlling how DNA operates, provides survival advantages to a subset of pancreatic cancer cells. The results, published in the Nature Genetics article, “Epigenomic Reprogramming during Pancreatic Cancer Progression Links Anabolic Glucose Metabolism to Distant Metastasis,” […]

Continue Reading

Liquid Biopsies About to Get a Billion Dollar Boost

| January 18, 2017 | 0 Comments

Grail, a company that aims to use a blood test to spot cancer, has announced a massive round of funding for its experimental approach. A billion dollars sounds like a lot of money. But when your ambitions are as big as the cancer-detection startup Grail Bio’s are, it might not be enough. As CEO and […]

Continue Reading

Register Now for CAP Webinar on HER2 Testing in Gastroesophageal Adenocarcinoma

| January 13, 2017 | 0 Comments

  In 2010, results of a phase 3 randomized controlled trial showed that targeted therapy directed against HER2 statistically significantly prolonged overall survival compared with chemotherapy alone in patients with HER2–positive advanced GEA. Because there are important differences in HER2 expression, scoring, and outcomes in GEA relative to breast carcinoma, the need for guideline recommendations […]

Continue Reading

ASCO, AMP and CAP Issue New Joint Consensus Statement to Standardize Interpretation and Reporting of Sequence Variants in Cancer

| January 3, 2017 | 0 Comments

Last month a joint consensus statement developed by ASCO, the Association for Molecular Pathology (AMP), and the College of American Pathologists (CAP) on standardizing the interpretation and reporting of sequence variants in cancer was published online ahead of the January print issue of The Journal of Molecular Diagnostics. Thank you to a loyal reader for the […]

Continue Reading

Cancer Moonshot Initiative Grounded

| November 23, 2016 | 0 Comments

Previous posts on this matter referenced that even with the funding proposed in the hundreds of millions dollars (estimated $750 million proposal) a lot more would be required. I believe one critic I referenced said that even with that amount of funding, if approved, wouldn’t “get us off the ground” when it came to this […]

Continue Reading

Young Survival Coalition Expresses Concern About Overlooked Moonshot Recommedations

| September 30, 2016 | 0 Comments

I haven’t written much about the President’s Cancer Moonshot initiative recently and as much as I would like – perhaps because following some Blue Ribbon Panel recommendations and a large number of organizations and individuals expressing, in general, positive feedback among the cancer community, there hasn’t been a lot of news about next steps.  I […]

Continue Reading

Dismissiveness of “Pinktober” Starting Early

| September 9, 2016 | 0 Comments

Last Fall I wrote a couple of posts about the growing disenchantment with ‘Pinkification’ and ‘Pinktober’ referencing the all-out blitz during October to go “Pink” for breast bancer awareness and prevention.  In one of the pieces I mentioned by disenchantment with what happened a number of years ago I saw in clinical practice and last […]

Continue Reading

Danaher to Buy Cepheid for $4 Billion

| September 7, 2016 | 0 Comments

Science, health care and technology conglomerate Danaher Corp. DHR 0.28 % said Tuesday that it would buy molecular-diagnostics company Cepheid Inc. CPHD -0.20 % for $53.00 a share, in its first major acquisition since spinning off a large chunk of its business. The deal marks a 54% premium over Cepheid’s closing share price Friday, valuing […]

Continue Reading

Computers Trounce Pathologists in Predicting Lung Cancer Type, Severity

| August 28, 2016 | 0 Comments

I love headlines such as these. First it was “Pigeons to Replace Pathologists in Diagnosing Benign from Malignant Tumors” now it is actual computer algorithms that get it right more times than and more so than ordinary surgical pathologists! Actually, I hope the pigeons do not get any more accurate but I do think that […]

Continue Reading

Vice President Biden Addresses Attendees at ASCO 2016

| June 7, 2016 | 0 Comments

“This is good news in the fight against cancer. With the launch of this new national resource, anyone can freely access raw genomic and clinical data for 12,000 patients – with more records to follow. Increasing the pool of researchers who can access data and decreasing the time it takes for them to review and […]

Continue Reading

FDA Approves First Liquid Biopsy Test for Use in Non-Small Cell Lung Cancer

| June 1, 2016 | 0 Comments

Exciting news today from FDA with news of approval of first liquid biopsy test for use in non-small cell lung cancer.  The cobas EGFR test is already approved for use in formalin-fixed paraffin-embedded (FFPE) tissue. This new use is intended for detection of these specific mutations in circulating-free tumor DNA (cfDNA) from plasma for first […]

Continue Reading

Mayo Clinic Awarded Funding to Support World’s Largest Research-Cohort Biobank

| May 27, 2016 | 0 Comments

As part of President Obama’s Precision Medicine Initiative (PMI), the National Institutes of Health will award $142 million over five years to the Mayo Clinic, Rochester, Minnesota, to establish the world’s largest research-cohort biobank for the PMI Cohort Program, a longitudinal research study which aims to enroll 1 million or more U.S. participants to advance precision medicine. […]

Continue Reading